Abstract
Background: Neoangiogenesis has recently become a major target for the development of new antineoplastic drugs. The most serious adverse events linked to angiogenesis inhibitors are venous/arterial thromboembolism and hemorrhage. Thus, there is a need to define with more certainty the impact of these new drugs in terms of adverse effects in neurological patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
